IPHA Innate Pharma S.A. Net earnings per share growth this year

IPHA (Innate Pharma S.A.) - company brandmark

Innate Pharma S.A. (IPHA) price action is driven by irregular partner payments, which creates revenue volatility due to the absence of mass-market sales. A comparison of annual EPS growth visualizes these fluctuations, where the 89.60 mark indicates the current state of earnings. Stability is maintained through efficient international antibody logistics, while prospective growth is driven by the development of NK-cell therapies within clinical trials.

Innate Pharma (IPHA): Net earnings per share growth this year from 07/04/2022 to 11/12/2026

Analytical breakdowns and data insights for company Innate Pharma S.A. (IPHA)

- current quotes and average value forecast:
Market Chart Innate Pharma SA|IPHA - Price Target Chart
- market capitalization data:
Market Valuation Innate Pharma S.A|IPHA - Total Company Value
- company book value details:
Accounting Value per Share Innate Pharma|IPHA - Company Net Assets|Market Capitalization to Book Value Ratio innate-pharma.com|IPHA - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Ratio Innate Pharma S.A.|IPHA - Long-Term Debt to Equity|Current Liabilities to Capital innate-pharma.com|IPHA - Company Total Debt|Debt to Net Assets Innate Pharma S.A|IPHA - Company Long-Term Liabilities|Amount of Current Liabilities Innate Pharma|Intermediate Coverage Ratio innate-pharma.com
- net income and valuation ratios data:
IPHA - Net Profit|Expected Net Profit Innate Pharma S.A.|IPHA - Price to Earnings Ratio|Future Price to Earnings Multiple Innate Pharma S.A|IPHA - PEG Multiple|EV/EBITDA Multiple Innate Pharma S.A|IPHA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Innate Pharma|IPHA - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months innate-pharma.com|IPHA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Innate Pharma S.A.
Summary company analysis:IPHA (Innate Pharma SA)
Brand item of Innate Pharma, S.A.

This indicator measures the year-over-year dynamics of earnings per share, allowing for an assessment of business capitalization efficiency relative to the previous period. By analyzing the annual evolution of earnings per share, investors can see the results of cost optimization at Innate Pharma S.A. (IPHA), where outsourcing commercial production to third-party contractors while maintaining full capacity at its own laboratories directly impacts final profitability.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year Immunocore PLC|Net earnings per share growth this year Janux Corp (JANX)|Earnings per share growth in current year Arcus Biosciences, Inc. (RCUS)|Net earnings per share growth this year zymeworks.com ZYME|Tango Therapeutics, Inc. - Net earnings per share growth this year|Earnings growth in current year Iovance Biotherapeutics Inc IOVA|IMTX - Earnings per share growth in current year|XNCR (Xencor Inc.) - Earnings per share growth this year|Compass Therapeutics (CMPX) - Earnings per share growth in current year|Earnings per share growth rate in current year replimune.com (REPL)|Net earnings per share growth this year LYEL|PYXS - Net earnings per share change in current year|Net earnings per share growth this year CGEN (Compugen Ltd.)|Net earnings per one share growth for the current year IOBT|Earnings growth in current year STRO (Sutro Biopharma, Inc.)|Earnings per share increase in current year INKT|Werewolf - Earnings growth in current year|Earnings per share growth rate in current year Immix Biopharma, Inc.|ALX Oncology (ALXO) - Earnings per share growth in current year|Cue Biopharma Inc. - Earnings per share increase in current year|PDSB (PDS Biotech) - Earnings growth in current year|Earnings growth in current year Sonnet BioTherapeutics Holdings Inc.|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|NextCure Corporation (NXTC) - Earnings per share growth rate in current year|Leap Tx - Earnings growth in current year|Expected net earnings per share growth this year Intensity Therapeutics INTS|senseibio.com (SNSE) - Earnings per share growth in current year|Earnings per share growth this year TOVX|Earnings per share growth in current year Gritstone bio Inc.|Earnings per share growth this year KA (Kineta Corp)|Earnings growth in current year NEXI|Earnings growth in current year turnstonebio.com (TSBX)|Vaccinex - Net earnings per share growth this year|Net earnings per one share growth for the current year HARP (Harpoon Therapeutics Inc)